IBJNews

Drug sold by Lilly tops Avastin in colon cancer survival study

Back to TopCommentsE-mailPrintBookmark and Share

Erbitux, a drug sold by Indianapolis-based Eli Lilly and Co., helped patients live longer than Roche Holding AG’s Avastin, a more commonly prescribed treatment, in a head-to-head test of the two drugs in patients with metastatic colon cancer.

Patients who got Erbitux together with chemotherapy as a first-line treatment lived about four months longer than those who got Avastin with chemotherapy, according to the 592-person study, dubbed Fire-3, presented Saturday at the American Society of Clinical Oncology’s meeting in Chicago.

Erbitux is marketed by Indianapolis-based Lilly and Bristol-Myers Squibb Co. in North America, and by Darmstadt, Germany-based Merck KGaA in Europe. Lilly realized about $400 million in revenue from the drug in 2012.

While unlikely to change doctors’ prescribing behavior alone, the unexpected results may focus attention on a bigger Erbitux-versus-Avastin study due next year, said Axel Grothey, a professor of oncology at the Mayo Clinic in Rochester, Minn. Both drugs are approved as initial therapies in colon cancer in the U.S., though Avastin is used more often, he said.

“If we see the same finding in this study, then I think it’s real,” Grothey said, referring to next year’s follow-up trial. “If we don’t see this result, then the Fire-3 trial is more or less a fluke. Before I would change my standard of care I would wait for these results.”

Patients lived about the same amount of time before their disease worsened, 10 months compared to 10.3 months, in the Erbitux and Avastin arms of the trial. Overall response rate, or shrinkage of tumors, the trial’s main data endpoint, were also the same.

The survival results emerged more than a year after most patients had stopped taking either drug, as the group that got initial treatment with Erbitux lived a median 28.7 months, compared to 25 months for those taking Avastin. The study only included the roughly 60 percent of colon cancer patients whose tumors have the non-mutated KRAS gene that makes Erbitux more likely to be effective.

Outcomes could have been influenced by differing access to therapies once initial treatment was over, Mayo’s Grothey said.

Though he wasn’t involved with the trial itself, Grothey will serve as chairman this weekend for a combined advisory board on the study for Erbitux partners Merck, Bristol-Myers Squibb and Lilly.

“These results are intriguing, but an unexplained positive finding from a secondary endpoint will not influence U.S. practice patterns,” Scott Kopetz, an associate professor of gastrointestinal medical oncology at the University of Texas MD Anderson Cancer Center, said in an e-mail.

About half the patients in each arm of the study switched to the opposite medicine—from Erbitux to Avastin, or vice versa—as a second treatment once their cancer had worsened, said Volker Heinemann, a professor of medical oncology at the Ludwig Maximilian University of Munich and lead author of the study. Full data on the treatment patients got once their cancer had worsened will be presented at the World Congress on Gastrointestinal Cancer in July, Heinemann said.

The results show that doctors who treat patients with the unmutated KRAS gene should choose Erbitux over Avastin, Heinemann said.

“For the moment we have to remain at that conclusion,” he said. “We are going to wait for support from the larger study. For the moment that is a reasonable conclusion.”

Roche looks forward to seeing full details of the study presented at the conference later today, spokesman Daniel Grotzky said in an e-mail before the results were released. Avastin is the Basel, Switzerland-based company’s third-biggest drug, with about $6 billion in sales last year.

Erbitux generated sales for Merck of 887 million euros $1.15 billion last year, with the majority of the revenue from initial use in metastatic colon cancer. The German company sells the medicine outside North America.

The survival benefit translated to a 23-percent lower risk of death for patients who got Erbitux, Merck said in an e-mailed statement. The German drugmaker said it looks forward to reviewing “emerging evidence” regarding how best to care for patients.

Germany’s Merck isn’t related to U.S. drugmaker Merck & Co.
 

ADVERTISEMENT

  • Find a Cure
    Come on lets find a cure, Lilly. Drugs are just to keep us hanging on until the next drug that helps the side effects of the first drug are realeased. Why do the drug companies play this game of being a poser to find a cure. It will most likely come from a forign country if they can get the information released before a big drug company buys it up and puts the hush on it. How can we find a cure for AIDS but not cancer??? I heard years ago if we ever find a cure for AIDS we will also find one for cancer?

Post a comment to this story

COMMENTS POLICY
We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
 
You are legally responsible for what you post and your anonymity is not guaranteed.
 
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
 
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
 
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.
 

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by
ADVERTISEMENT

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
 
Subscribe to IBJ
  1. Uh, sorry Johnnie, but you are incorrect. Despite the assertions by yourself and various defenders and captains, sports attendance is NOT off significantly at most sporting events in the US. Variances in attendance has been in the range of single digits, both + & - for years now. MLB has had most of its best overall attendance nubers in the last decade, and that trend has been consistent for most major sporting events. The number one issue cited by most fans when asked about attendance is the overall cost of attending. The presence of HD and big screen televisions in home doesn't even register, as a factor for not attending an event. VALUE in the product is the key, and apparently is something lacking in the current ICS. What other explanation is there when with what is routinely touted as the "best" racing on the planet, fans are staying away in DROVES. A "close" title battle into the last event at Fontana, with the "cars and stars" of the ICS, and who showed up? MAYBE 8K. Sorry, but HD TV isn't to blame for that kind of fan apathy.

  2. Do you need finance to establish your business ? Are you interested in getting a loan at 3% from our private company? If so please Email: suntrust_oil@blumail.org

  3. If she was worth the $ the public outcry over direct tv dropping them would have kept them on their dishes as we have seen with other companies. I too quit watching channel 13 after she showed up since I left channel 8 because of her all show rather than production results. When Randy on 8 corrected her she had a big head and incorrectly challenged his correction for pronunciation of a city. Other antics while she matures was too much for me with her very inaccurate forecasts. All the forecasters were predicting rain until Thursday except Chris. They predicted sunny on Thursday but instead of rain until Thursday upon which the sun would finally make it out in full glory Chris was right on the money just as I too predicted looking at the radar on weather.gov. One thing I love about Angela is the fear you can see in her every time it thunders in the winter. It far exceeds the entertainment value of her body language (high heel noise drags, depression, etc) when her forecasts are so incorrect. Her hair stands on end, you have to see it!!!

  4. Good Day, Apply For A Loan I am Mr Fernadez Antonio, a private Loan lender and a cooperate financial for real estate and any kinds of business financing. I also offer Loans to individuals, Firms and cooperate bodies at 3% interest rate We offer any kind of loans. email us via fernadezloaninvest@outlook.com LOAN APPLICATION FORM First name:......................... Middle name:......................... Last name:........................................ Date of birth (yyyy-mm-dd):....................... Gender:........................................... Marital status:................................... Total Amount Needed............................... Loan Duration.................................... Address:.......................................... City:............................................. State/province:................................... Zip/postal code:.................................. Country:.......................................... Phone:............................................ Fax:.............................................. Mobile/cellular:.................................. Monthly Income.................................... Occupation:....................................... Best Regard, Mr Fernadez Antonio.

  5. i will love to share my testimony to you all the people in world i got married to my husband about 2 year ago we start having problems at home like we stop sleeping on the same bed,fighting about little things he always comes home late at night,drinking too much and sleeping with other women out side i have never love any man in my life except him. he is the father of my child and i don't want to loose him because we have worked so hard together to become what we are and have today .few month ago he now decided to live me and the kid,being a single mother can be hard sometimes and so i have nobody to turn to and i was heart broken.i called my mom and explain every thing to her,my mother told me about DR.okoro how he helped her solve the problem between her and my dad i was surprise about it because they have been without each other for three and a half years and it was like a miracle how they came back to each other. i was directed to DR. okoro on his email:okorospell@gmail.com and explain everything to him,so he promise me not to worry that he will cast a spell and make things come back to how we where so much in love again and that it was another female spirit that was controlling my husband he told me that my problem will be solved within two days if i believe i said OK So he cast a spell for me and after two days my love came back asking me to forgive him i Am so happy now. so that why i decided to share my experience with every body that have such problem contact Dr okoro the great spell caster on his email addresses spellcasterforlove@outlook.com

ADVERTISEMENT